Androgen-driven fusion genes and chimeric transcripts in prostate cancer

M Scaravilli, S Koivukoski, L Latonen - Frontiers in Cell and …, 2021 - frontiersin.org
Androgens are steroid hormones governing the male reproductive development and
function. As such, androgens and the key mediator of their effects, androgen receptor (AR) …

Oncogenic ETS factors in prostate cancer

TR Nicholas, BG Strittmatter, PC Hollenhorst - Prostate Cancer: Cellular …, 2019 - Springer
Prostate cancer is unique among carcinomas in that a fusion gene created by a
chromosomal rearrangement is a common driver of the disease. The TMPRSS2/ERG …

Random forest-based modelling to detect biomarkers for prostate cancer progression

R Toth, H Schiffmann, C Hube-Magg, F Büscheck… - Clinical …, 2019 - Springer
Background The clinical course of prostate cancer (PCa) is highly variable, demanding an
individualized approach to therapy. Overtreatment of indolent PCa cases, which likely do not …

Spontaneous expression of the CIC:: DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma formation in genetically engineered mice

PG Hendrickson, KM Oristian, MKR Browne, L Luo… - Oncogene, 2024 - nature.com
Abstract CIC:: DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small
round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and …

Pan-cancer analysis of the mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer

J Brägelmann, N Klümper, A Offermann… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: The Mediator complex is a multiprotein assembly, which serves as a hub
for diverse signaling pathways to regulate gene expression. Because gene expression is …

Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer

KT Carm, AM Hoff, AC Bakken, U Axcrona, K Axcrona… - Scientific reports, 2019 - nature.com
Prostate cancer is a highly heterogeneous disease and typically multiple distinct cancer foci
are present at primary diagnosis. Molecular classification of prostate cancer can potentially …

E26 transformation-specific variant 4 as a tumor promotor in human cancers through specific molecular mechanisms

W Jiang, Y Xu, X Chen, S Pan, X Zhu - Molecular Therapy-Oncolytics, 2021 - cell.com
E26 transformation-specific (ETS) variant 4 (ETV4) is an important transcription factor that
belongs to the ETS transcription factor family and is essential for much cellular physiology …

The ETS family transcription factors Etv5 and PU. 1 function in parallel to promote Th9 cell development

B Koh, MM Hufford, D Pham, MR Olson… - The Journal of …, 2016 - journals.aai.org
Abstract The IL-9–secreting Th9 subset of CD4 Th cells develop in response to an
environment containing IL-4 and TGF-β, promoting allergic disease, autoimmunity, and …

ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21

I Cosi, A Pellecchia, E De Lorenzo, E Torre… - Journal of hematology & …, 2020 - Springer
Background ETV4 is one of the ETS proteins overexpressed in prostate cancer (PC) as a
result of recurrent chromosomal translocations. In human prostate cell lines, ETV4 promotes …

ETS1, ELK1, and ETV4 transcription factors regulate angiopoietin-1 signaling and the angiogenic response in endothelial cells

S Harel, V Sanchez, A Moamer… - Frontiers in …, 2021 - frontiersin.org
Background Angiopoietin-1 (Ang-1) is the main ligand of Tie-2 receptors. It promotes
endothelial cell (EC) survival, migration, and differentiation. Little is known about the …